anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An apparatus (1) includes an exercise sensor (31) that continuously detects a movement of an exerciser accompanied by intermittent exercise, and a heart rate meter (32) that continuously measures a heart rate of the exerciser, and further includes an activity detection unit (12), a heart rate monitoring unit (13), an activity monitoring unit (14), and a notification processing unit (15). The activity detection unit (12) detects, from the movement of the exerciser, an activity intensity, a high activity intensity period, and a low activity intensity period. The heart rate monitoring unit (13) detects a declining trend in the heart rate of the exerciser, in the low activity intensity period each time, and monitors whether or not the declining trend of this time is low as compared with a predetermined reference. The activity monitoring unit (14), in a case in which the monitoring by the heart rate monitoring unit is affirmed, monitors whether or not the activity intensity to be detected in the high activity intensity period of a next time is low as compared with activity intensities detected in high activity intensity periods up to a previous time. The notification processing unit (15), in a case in which the monitoring by the activity monitoring unit is affirmed, forecasts an outbreak of disease. With this configuration, the outbreak of disease in an exerciser during an exercise is forecasted with higher accuracy.
The successes of psychological and pharmacological modes of intervention in treating depression, both alone and combined, are well documented in the literature. While a great deal of research has identified specific clinical indications for many antidepressants currently available in the general population, little is known about the clinical indications of these agents in SCI. This study is proposed to test the benefits of Venlafaxine HCI (Effexor XR) for reducing mild to moderate symptoms of depression among people with SCI. The intervention will last 12 weeks and there will be 13 assessments and data collection points. Data will be collected at 26 weeks also. Eight face to face contacts are anticipated.

Because of the change in protocol to reducing mild to moderate symptoms and substantially lower enrollment than anticipated (1/6th of what we anticipated), we deleted a number of study outcomes listed in the 2011 posting of this study. Most of these were not part of the original posting in 2008, and those that were deleted were no longer relevant to new protocol's focus on reducing mild to moderate depression. The two outcomes reported here were most relevant to the revised protocol.
The invention is a code to incorporate variant information into omics data. The omics data so obtained could be used for determining the biomolecules, pathways, deciphering the taxonomy, probe designing, understanding evolutionary transitions at the omics level, data analysis, annotation, interpretation, visualization and any further studies. The omics data obtained after incorporation of variants is in compliance with the file formats of omics data and can be used as any other omics data in Bioinformatics software(s) or as standalone tool. The code could be hosted as an online tool. The code has been originally developed using R. The invention involves approaches to enable editing of omics data, using code which transforms the data type, manipulates, incorporate information in a sequential manner and converts them back to the same omics file format specification. The code could be written using various programming languages and compatible with all operating systems.
The present invention describes purified genes encoding cytokines from a mammal, reagents related to this process including purified proteins, specific antibodies and nucleic acids encoding these molecules. In the concrete, the aim of this invention is an isolated or recombinant polynucleotide encoding polypeptide selected from a group consisting of SEQ ID NO: 2, 4 and 5. Said polynucleotide advantageously contains coding sequences SEQ ID NO: 1 or 3. Another aim of the invention is an isolated or recombinant polynucleotide encoding mature polypeptide from SEQ ID NO: 2 or 4. In advantageous form this polypeptide contains nucleotides 64 to 567 from SEQ ID NO: 1 or nucleotides 176 to 700 from SEQ ID NO: 3. Further objects of the invention are expression vector, host cell, method of polypeptide preparation, antibody or its antigen binding fragment and a method for detection of antigen presence in a biologic specimen.
Spine pain is a common condition that results in considerable levels of disability and lost work time and has a major impact on society, a lifetime prevalence ranging from 15.6% to 19.5% for thoracic pain. Thoracic pain is more prevalent in women than in men (2:1). The origin of spine pain is clearly multifactorial and often includes number of anatomical structures. One plausible etiology of symptoms associated with thoracic pain may be the presence of myofascial pain. Myofascial pain is generally associated with the presence of trigger points. Trigger points are hypersensitive spots within taut bands of skeletal musculature whose stimulation can be associated with referred pain and autonomic phenomena. Trigger points can be either active or latent depending on the association with symptoms. For instance, active trigger points (MTrPs) are associated with spontaneous pain, and the local and referred pain reproduces the symptoms of the patient, totally or partially.

Stripping massage (SM) is a gliding tissue massage technique that focuses on the deeper layers of the fascia and skeletal muscle.This technique involves gliding pressure along a muscle, usually from one attachment to the other in the direction of the muscle fibers. Applying SM to tender spots in muscles can cause ischaemia followed by reflexive hyperaemia. This increases the local blood flow, which improves pliability of the muscles and fascia and helps break down adhesions and decrease pain sensations. SM acts as a mechanical stress that stimulates parasympathetic activity which leads to the release of substances such as endorphins. These chemicals remove the noxious stimulus and decrease the pressure on nociceptors, reducing pain The rationale for the use of this technique is to identify the effects of stripping massage on rhomboids active trigger points in upper thoracic pain patients. This study will see the effects of stripping massage on rhomboids trigger points on pain, thoracic mobility, and functional performance. Aim of this study is to see the effects of stripping massage to figure out whether this technique would be more effective and should be incorporated into clinical settings in relation to conventional treatment.
Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Oxycodone and aspirin tablets may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics). Monitor these patients for signs of hypotension after initiating or titrating the dosage of oxycodone and aspirin tablets. In patients with circulatory shock, oxycodone and aspirin tablets may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of oxycodone and aspirin tablets in patients with circulatory shock.
BACKGROUND: Coma is an unresponsive state of disordered consciousness characterized by impaired arousal and awareness. The epidemiology and pathophysiology of coma in ischemic stroke has been underexplored. We sought to characterize the incidence and clinical features of coma as a presentation of large vessel occlusion (LVO) stroke.
METHODS: Individuals who presented with LVO were retrospectively identified from July 2018 to December 2020. Coma was defined as an unresponsive state of impaired arousal and awareness, operationalized as a score of 3 on NIHSS item 1a.
RESULTS: 28/637 (4.4%) patients with LVO stroke were identified as presenting with coma. The median NIHSS was 32 (IQR 29-34) for those with coma versus 11 (5-18) for those without (p < 0.0001). In coma, occlusion locations included basilar (13), vertebral (2), internal carotid (5), and middle cerebral (9) arteries. 8/28 were treated with endovascular thrombectomy (EVT), and 20/28 died during the admission. 65% of patients not treated with EVT had delayed presentations or large established infarcts. In models accounting for pre-stroke mRS, basilar occlusion location, intravenous thrombolysis, and EVT, coma independently increased the odds of transitioning to comfort care during admission (aOR 6.75; 95% CI 2.87,15.84; p < 0.001) and decreased the odds of 90-day mRS 0-2 (aOR 0.12; 95% CI 0.03,0.55; p = 0.007).
CONCLUSIONS: It is not uncommon for patients with LVO to present with coma, and delayed recognition of LVO can lead to poor outcomes, emphasizing the need for maintaining a high index of suspicion. While more commonly thought to result from posterior LVO, coma in our cohort was similarly likely to result from anterior LVO. Efforts to improve early diagnosis and care of patients with LVO presenting with coma are crucial.
A quick and easy system and method for delivering a viscous medical solution to a nasal membrane is presented. The applicator assembly includes a sleeve member which encases a swab having a portion that contacts a gelled solution. The sleeve member is manually severed to expose the applicator and the solution. The gelled solution contained on the applicator is applied to the nasal membrane. The solution has a viscosity in the range 1500 to 40 000 centipoise. The composition of the solution comprises a carrier liquid, thickening agents, emulsifiers, preservatives, buffers permeation enhancers and medical active substances.
Natural menopause can be defined as the cessation of menses for twelve sequential months without physiological or pathologic causes, referring to the end of a woman's reproductive capability. There is considerable variation in reporting of menopausal symptoms by women all over the world in different studies. The most common psychological symptoms was physical, mental exhaustion and Sleep disturbances. Sleep quality is affected poorly during the menopausal transition, and 40-60% of menopausal women are suffering from sleep disturbances. The causes for sleep disorders in postmenopausal women can be divided broadly into psychological and physical. However, changes in sleep patterns after menopause are frequently the result of physical factors. Sleep quality and its effect on quality of life among postmenopausal women is vital topic and the previous Literatures in this topic are deficient. So, there is a need to study sleep quality and quality of life particularly in our population where women are less aware about menopausal symptoms.
OBJECTIVE: To determine the effectiveness of pediatric Tuina (PT) in preventing recurrent acute respiratory tract infections (ARTIs) in children.
METHODS: This is a retrospective cohort study based on the electronic medical records of children with recurrent ARTIs in 2016. Children were divided into a PT group or a non-PT group, according to whether they had received PT or not in 2016. The primary outcome was the number of ARTI episodes in 2017 and 2018. The secondary outcomes were the number of ARTIs leading to outpatient department visits and outpatient antibiotic prescriptions due to ARTIs in the same time period. Negative binomial regressions were used to detect the association between PT and the outcomes.
RESULTS: A total of 2303 children were included in the analysis, including 94 in the PT group and 2209 in the non-PT group. Children who received PT six or more times in 2016 had fewer episodes of ARTIs in 2017 [incidence rate ratio (IRR): 0.59, 95% confidence interval (CI) (0.42-0.84)] and 2018 [IRR: 0.58, 95% CI (0.36-0.94)] and fewer outpatient department visits due to ARTIs in 2017 [IRR: 0.56, 95% CI (0.38-0.83)] than children who had not received PT in 2016. There was no significant difference in the number of outpatient antibiotic prescriptions between the two groups.
CONCLUSIONS: Receiving PT six or more times within one year is associated with a decrease in recurrent ARTIs in children in the following two years. Randomized controlled trials are needed for effect evaluation prior to establishing PT as a method for preventing recurrent ARTIs among children.
Dry eye disease (DED) is a common and frequent ocular surface disease worldwide, which can cause severe ocular surface discomfort and blurred vision. Inflammation and reactive oxygen species (ROS) play decisive roles in the development of DED. However, existing treatments usually focus on anti-inflammation while ignore the role of ROS in DED. Ever worse, the clinical preparations are easily cleared by nasolacrimal ducts, resulting in poor therapeutic effect. To circumvent these obstacles, here we designed a phenylboronic acid (PBA) modified liposome co-loading immunosuppressant cyclosporin A (CsA) and antioxidant crocin (Cro). The CsA/Cro PBA Lip achieved mucoadhesion through the formation of covalent bonds between PBA and the sialic acid residues on mucin, and consequently improved the retention of drugs on the ocular surface. By inhibiting ROS production and blocking NF-κB inflammatory pathway, CsA/Cro PBA Lip successfully promoted the healing of damaged corneal epithelium, eventually achieving the goal of relieving DED. CsA/Cro PBA Lip is proven a simple yet effective dual-drug delivery system, exhibiting superior antioxidant and anti-inflammatory effects both in vitro and in vivo. This approach holds great potential in the clinical treatment of DED and other related mucosal inflammations.
The accumulation of visceral adipose tissue (VAT) is strongly associated with cardiovascular disease and diabetes. In contrast, individuals with increased subcutaneous adipose tissue (SAT) without corresponding increases in VAT are associated with a metabolic healthy obese phenotype. These observations implicate dysfunctional VAT as a driver of disease processes, warranting investigation into obesity-induced alterations of distinct adipose depots. To determine the effects of obesity on adipose gene expression, male mice (n = 4) were fed a high-fat diet to induce obesity or a normal laboratory diet (lean controls) for 12-14 mo. Mesenteric VAT and inguinal SAT were isolated for bulk RNA sequencing. AT from lean controls served as a reference to obesity-induced changes. The long-term high-fat diet induced the expression of 169 and 814 unique genes in SAT and VAT, respectively. SAT from obese mice exhibited 308 differentially expressed genes (164 upregulated and 144 downregulated). VAT from obese mice exhibited 690 differentially expressed genes (262 genes upregulated and 428 downregulated). KEGG pathway and GO analyses revealed that metabolic pathways were upregulated in SAT versus downregulated in VAT while inflammatory signaling was upregulated in VAT. We next determined common genes that were differentially regulated between SAT and VAT in response to obesity and identified four genes that exhibited this profile: elovl6 and kcnj15 were upregulated in SAT/downregulated in VAT while trdn and hspb7 were downregulated in SAT/upregulated in VAT. We propose that these genes in particular should be further pursued to determine their roles in SAT versus VAT with respect to obesity.NEW & NOTEWORTHY A long-term high-fat diet induced the expression of more than 980 unique genes across subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). The high-fat diet also induced the differential expression of nearly 1,000 AT genes. We identified four genes that were oppositely expressed in SAT versus VAT in response to the high-fat diet and propose that these genes in particular may serve as promising targets aimed at resolving VAT dysfunction in obesity.
Sensitivity is low for prediction of long term survival of currently available prognostic scores for brain metastases. First the current clinical models will be optimized with a new prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. These tumor characteristics may reflect tumor biology and outcome. Therefore it is investigated if radiomics improves prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics for local failure is investigated.
BACKGROUND: PDZ And LIM domain protein 1 (PDLIM1), a protein-coding gene, has been widely reported to exhibit differential expression patterns across various human cancers, including hematological malignancies. This study aimed to investigate PDLIM1 expression pattern and its functional role in diffuse large B-cell lymphoma (DLBCL) both in vitro and in vivo.
METHODS: PDLIM1 expression patterns were reanalyzed using data from the Gene Expression Omnibus, and the results were subsequently validated in patient tissue samples and a panel of four DLBCL cell lines. MicroRNA-3940-5p (miR-3940-5p) was identified as an upstream regulator of PDLIM1. The interaction between PDLIM1 and miR-3940-5p and its effects on DLBCL cellular activities and cancer development were further explored using a DLBCL mouse model.
RESULTS: Elevated PDLIM1 expression was observed in DLBCL cells and tissues. Reduced cell proliferation and increased DLBCL cell apoptosis were observed following the knockdown of this gene. Furthermore, short hairpin RNA (shRNA)-mediated PDLIM1 knockdown diminished tumorigenesis of DLBCL cells in nude mice. miR-3940-5p was identified as an upstream regulator of PDLIM1. PDLIM1 expression and function were negatively modulated by the upregulation of miR-3940-5p, consequently affecting the malignant phenotype of DLBCL cells.
CONCLUSION: These findings suggest that the miR-3940-5p/PDLIM1 axis may play a crucial role in DLBCL pathogenesis and could potentially be exploited for therapeutic interventions.
R/R AML who are ineligible for intensive chemotherapy will receive selinexor in combination with chidamide, 28 days per cycle, Selinexor will be used as 40 or 60mg BIW for two weeks, and chidamide will be used as 10mg/d from day 1 to 28. Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.
non probability convenient sampling was done. patients following eligibility criteria from Madina Teaching Hospital FSD and Kadijatulkubra hospital Chiniot. Non Probability Convenient sampling was done. Sample size was calculated with G power. 28 Participants were randomly allocated in two groups equally via convenient sampling method. Baseline assessment was done initially. Group A was given neural glides and Group B was given PNF along with conventional physiotherapy treatment (hot pack and traction). Duration of research was almost 6 months. Intervention was applied for 4 weeks, 3 sessions per week. Pre and Post treatment readings were taken in 1st and 4th week session Assessment was done via Numeric Pain Rating Scale; NDI, CVA and JPE as subjective measurements. All participants were provided written informed consent prior to commencement of the procedures. They were free to quit the treatment at any stage of research. Data was analyzed by using SPSS version 23.
PROBLEM TO BE SOLVED: To obtain a molding material for incense which can give a variety in color to the incense and vary the odor of the incense with the passage of time, when the incense is fumigated, by mixing fine powders of Chinese medicines and perfumes different in color and smell. SOLUTION: Fine powders of Chinese medicines and perfumes, vehicles and inorganic components are mixed, a desired pigment and a binder are admixed, they are granulated to form granules of a single color. Then, granules different in color are admixed. The size of the grains is preferably 150-1,300μm. At least two kinds of the grains included in the molding material for incense have the density difference in the range of 0-0.2g/ml and the average particle size or the distribution of particle sizes are preferably in the same ranges. This material is charged in a mold to effect compression molding to give incense. Chinese medicines and perfumes are, for example, aloeswood, agalloch, sandalwood, cinnamon bark, clove, spikenard, frankincense, benzoin and other perfumes from southern Asia.
The invention relates to a slow release formulation which is composed of moxifloxacin hydrochloride, officinal slow release materials and other officinal auxiliary materials. The slow release formulation can be divided into two parts, i.e. a quick release part and a slow release part, can be a bilayer tablet pressed by a double-layer tablet press or is slow release capsule composed of drugs of two parts, i.e. a quick release part and a slow release. The slow release formulation of the invention can cause drug to quickly become effective, can maintain the effective concentration of the drug for a long term and has ideal therapeutic effect. The invention also relates to a preparation method of the slow release formulation.
There are 79 female participants in this group. After the pre-test, participants in the experimental group were given breast cancer and breast self-examination training. After the training, they were reminded to do breast self-examination by phone for six months. The post-test was administered six months later.
To provide a novel atopic dermatitis prevention/treatment agent.SOLUTION: The features of the present invention for solving the above problems are as follows. 1. A filaggrin expression promoter under atopic dermatitis containing β-sitosterol glucoside as an active ingredient. 2. An agent for reducing transepidermal water loss under atopic dermatitis, containing β-sitosterol glucoside as an active ingredient. 3. A skin barrier function improving agent under atopic dermatitis containing β-sitosterol glucoside as an active ingredient. 4. A preventive/therapeutic agent for atopic dermatitis containing the agent described in above 1.-above 3. 5. A preventive/therapeutic agent for atopic dermatitis containing β-sitosterol glucoside as an active ingredient.SELECTED DRAWING: None
This study aims to identify neuroimaging biomarkers for predicting mild cognitive impairment (MCI) in breast cancer patients receiving adjuvant chemo and/or hormonal therapy by examining hippocampal-cortical neurocircuitry. Adjuvant therapies increase long-term survival, but produce changes in cognitive function in 30% (up to 70%) of women on average with breast cancer. Cognitive decline negatively impacts quality of life in patients and their supporters. Therefore, early identification of patients at risk for developing treatment-related cognitive impairment is needed to develop potential prevention or treatment options and prevent further decline. Our recent work demonstrates that patients receiving adjuvant hormonal treatment exhibit decline in cognition as soon as three months post treatment. Although neuroimaging studies have identified brain changes associated with chemotherapy ("chemo brain", no investigation has assessed the type and severity of such changes following hormonal therapy, nor has any study determined which individuals are at greatest risk for cognitive impairment.

Our central hypothesis is that measures of the hippocampal-cortical integrity can be used to predict cognitive decline, and changes of specific domains of cognitive performance in patients receiving adjuvant therapy over time will be related to changes in specific components of this circuitry over time.